Maternal Smoking and Congenital Heart Defects, National Birth Defects Prevention Study, 1997-2011

Bolin, Elijah H.; Gokun, Yevgeniya; Romitti, Paul A.; Tinker, Sarah C.; Summers, April D; Roberson, Paula K.; Hobbs, Charlotte A.; Malik, Sadia; Botto, Lorenzo D.; Nembhard, Wendy N.

doi:10.1016/j.jpeds.2021.09.005

Cited by 17 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We note that in the present study were tobacco and alcohol use were unrelated or were negatively related to CAR’s. This findings is at variance with other results such as those previously reported from North America [ 8 , 74 ]. Such differing results will require further research.…”

Section: Discussioncontrasting

confidence: 65%

European epidemiological patterns of cannabis- and substance-related congenital cardiovascular anomalies: geospatiotemporal and causal inferential study

Reece

Hulse

2022

Environmental Epigenetics

View full text Add to dashboard Cite

As prenatal and community cannabis exposures have recently been linked with congenital heart disease (CHD), it was of interest to explore these associations in Europe in a causal framework and space-time context. Congenital anomaly data from Eurocat, drug-use data from the European Monitoring Centre for Drugs and Drug Addiction, and income from the World Bank. Countries with rising daily cannabis use had in general higher congenital anomaly rates over time than those without (time: status interaction: β-Est. = 0.0267, P = 0.0059). At inverse probability-weighted panel regression, cannabis terms were positive and significant for CHD, severe CHD, atrial septal defect, ventricular septal defect, atrioventricular septal defect, patent ductus arteriosus, tetralogy of Fallot, vascular disruptions, double outlet right ventricle, transposition of the great vessels, hypoplastic right heart, and mitral valve anomalies from 1.75 × 10−19, 4.20 × 10−11, <2.2 × 10−16, <2.2 × 10−16, 1.58 × 10−12, 4.30 × 10−9, 4.36 × 10−16, 3.50 × 10−8, 5.35 × 10−12, <2.2 × 10−16, 5.65 × 10−5 and 6.06 × 10−10. At spatial regression, terms including cannabis were positive and significant for this same list of anomalies from 0.0038, 1.05 × 10−10, 0.0215, 8.94 × 10−6, 1.23 × 10−5, 2.05 × 10−5, 1.07 × 10−6, 8.77 × 10−5, 9.11 × 10−6, 0.0001, 3.10 × 10−7 and 2.17 × 10−7. 92.6% and 75.2% of 149 E-value estimates and minimum E-values were in high zone >9; 100.0% and 98.7% >1.25. Data show many congenital cardiac anomalies exhibit strong bivariate relationships with metrics of cannabis exposure. Causal inferential modelling for the twelve anomalies selected demonstrated convincing evidence of robust relationships to cannabis which survived adjustment and fulfilled epidemiological criteria for causal relationships. Space-time regression was similarly confirmatory. Epigenomic pathways constitute viable potential mechanisms. Given exponential genotoxic dose-response effects, careful and astute control of cannabinoid penetration is indicated.

show abstract

Section: Discussioncontrasting

confidence: 65%

European epidemiological patterns of cannabis- and substance-related congenital cardiovascular anomalies: geospatiotemporal and causal inferential study

Reece

Hulse

2022

Environmental Epigenetics

View full text Add to dashboard Cite

show abstract

“…There was not a significant association between this exposure and truncus arteriosus (OR, 1.2 [95% CI, 0.7–2.1]) and Ebstein anomaly (OR, 1.1 [95% CI, 0.7–1.8]). 25 Exposure to secondhand smoke also has been implicated as a risk factor for CCDs. 23…”

Section: Congenital Cardiovascular Defects and Kawasaki Diseasementioning

confidence: 99%

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Martin,

Aday,

Almarzooq

et al. 2024

Circulation

216

View full text Add to dashboard Cite

BACKGROUND: The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, and obesity) and health factors (cholesterol, blood pressure, glucose control, and metabolic syndrome) that contribute to cardiovascular health. The AHA Heart Disease and Stroke Statistical Update presents the latest data on a range of major clinical heart and circulatory disease conditions (including stroke, brain health, complications of pregnancy, kidney disease, congenital heart disease, rhythm disorders, sudden cardiac arrest, subclinical atherosclerosis, coronary heart disease, cardiomyopathy, heart failure, valvular disease, venous thromboembolism, and peripheral artery disease) and the associated outcomes (including quality of care, procedures, and economic costs). METHODS: The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing. The 2024 AHA Statistical Update is the product of a full year’s worth of effort in 2023 by dedicated volunteer clinicians and scientists, committed government professionals, and AHA staff members. The AHA strives to further understand and help heal health problems inflicted by structural racism, a public health crisis that can significantly damage physical and mental health and perpetuate disparities in access to health care, education, income, housing, and several other factors vital to healthy lives. This year’s edition includes additional global data, as well as data on the monitoring and benefits of cardiovascular health in the population, with an enhanced focus on health equity across several key domains. RESULTS: Each of the chapters in the Statistical Update focuses on a different topic related to heart disease and stroke statistics. CONCLUSIONS: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.

show abstract

“…There is evidence that cigarette smoking increases the rate of caffeine metabolism and that higher cigarette consumption is associated with increased coffee consumption (Bjørngaard et al, 2017). Many of the defects we observed to have significant positive associations with caffeine consumption have been shown to be associated with maternal smoking, including oral clefts, craniosynostosis, and septal defects (Bolin et al, 2022; Carmichael et al, 2008; Little et al, 2004). While we did control for maternal smoking in our multivariable analyses, there may be residual confounding by maternal smoking for maternal caffeine consumption and the risk of birth defects.…”

Section: Discussionmentioning

confidence: 68%

Maternal dietary caffeine consumption and risk of birth defects in the National Birth Defects Prevention Study, 1997–2011

Williford

Howley

Fisher

et al. 2023

Birth Defects Research

Self Cite

View full text Add to dashboard Cite

Background: Caffeine consumption is common during pregnancy, but published associations with birth defects are mixed. We updated estimates of associations between prepregnancy caffeine consumption and 48 specific birth defects from the National Birth Defects Prevention Study (NBDPS) for deliveries from 1997 to 2011.Methods: NBDPS was a large population-based case-control study conducted in 10 U.S. states. We categorized self-reported total dietary caffeine consumption (mg/day) from coffee, tea, soda, and chocolate as: <10, 10 to <100, 100 to <200, 200 to <300, and ≥ 300. We used logistic regression to estimate adjusted odds ratios (aORs [95% confidence intervals]). Analyses for defects with ≥5 exposed case children were adjusted for maternal race/ethnicity, age at delivery, body mass index, early pregnancy cigarette smoking and alcohol use, and study site. Results: Our analysis included 30,285 case and 11,502 control children, with mothers of 52% and 54%, respectively, reporting consuming <100 mg caffeine, and 11% of mothers of both cases and controls reported consuming ≥300 mg per day. Low (10 to <100 mg/day) levels of prepregnancy caffeine consumption were associated with statistically significant increases in aORs (1.2-1.7) for 10 defects. Associations with high (≥300 mg/day) levels of caffeine were generally weaker, except for craniosynostosis and aortic stenosis (aORsConclusions: Given the large number of estimates generated, some of the statistically significant results may be due to chance and thus the weakly increased aORs should be interpreted cautiously. This study supports previous observations suggesting lack of evidence for meaningful associations between caffeine consumption and the studied birth defects.

show abstract

Maternal Smoking and Congenital Heart Defects, National Birth Defects Prevention Study, 1997-2011

Cited by 17 publications

References 38 publications

European epidemiological patterns of cannabis- and substance-related congenital cardiovascular anomalies: geospatiotemporal and causal inferential study

European epidemiological patterns of cannabis- and substance-related congenital cardiovascular anomalies: geospatiotemporal and causal inferential study

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Maternal dietary caffeine consumption and risk of birth defects in the National Birth Defects Prevention Study, 1997–2011

Contact Info

Product

Resources

About